Skip to content
Markets

Bayer Extends Its 15% Rally on a Roundup Jury Win and an Upgraded Outlook

Bayer shares rose about 5% after it raised its 2026 profit outlook on a strong pharma quarter, extending a 15% gain last week that followed a Roundup jury win. Q3 EBITDA beat forecasts by 13%.

Lorries at a gate of the Bayer works in Leverkusen, Germany, with chimneys behind and the outline of the Bayer cross hanging between two masts in the background.
Photo: Rutger van der Maar / Flickr, CC BY 2.0

Bayer shares rose about 5% on Tuesday after the company raised its 2026 profit outlook on the back of a strong quarter in pharmaceuticals. Third-quarter EBITDA before special items of €1.62bn was about 13% above analysts' expectations. The gain extends a 15.01% rally last week, when a US jury found for Bayer's Monsanto unit in the first Roundup trial since a Supreme Court ruling in June.

The shares were trading about 5% higher by 10:44 GMT, according to Reuters. They closed last week at €50.58, up from €43.98 a week earlier, the second-best weekly gain among tracked stocks.

Bayer, third quarter

  • +15.01% shares, week to 30 October
  • €1.62bn EBITDA before special items, up 6.9%
  • +58% Nubeqa sales, to about €1bn

A Jury Verdict Started the Run

The rally began with a court win. On 29 October a St. Louis County jury returned a unanimous verdict for Monsanto on all claims brought by three plaintiffs in the Aretino case.

It was the first Roundup trial since the US Supreme Court's Durnell decision in June. That ruling held that federal pesticide law overrides state-law failure-to-warn claims where the Environmental Protection Agency has made a definitive safety finding. With those claims gone, the plaintiffs pursued design defect, negligence and fraud claims instead, and lost.

Separately, Bayer wants a $7.25bn settlement to resolve tens of thousands of other Roundup claims. A Missouri state court judge in St. Louis is reviewing it. Chief executive Bill Anderson expects approval before Christmas and said on Tuesday that it could come any week now.

Bayer: share price, chart and news

Pharma Drives the Upgrade

The quarter itself was uneven, but the strong parts were strong. Group sales rose 4.1% to €10.05bn, or 1.9% after currency and portfolio effects, and EBITDA before special items rose 6.9% to €1.615bn.

Pharmaceuticals did most of the work. Sales rose 8% to €4.68bn, about 5% above the Vara Research poll, and the division's EBITDA before special items climbed 23.6% to €1.29bn, a margin of 27.6%. The prostate cancer drug Nubeqa grew 58% to about €1bn in the quarter and the kidney drug Kerendia 65%, both on a currency-adjusted basis. "We've reached a turning point in Pharma's growth trajectory," Anderson said.

Crop Science saw EBITDA before special items fall 41.3% to €101m. Consumer Health slipped 4.4% to €347m.

Below the operating line the picture was weaker. Bayer booked a €307m impairment on the cancer drug Xofigo, and its €407m of net special charges included a €215m impairment on the Claritin allergy brand. The net loss narrowed to €672m from €963m. Core earnings per share fell to €0.31 from €0.49, and free cash flow was negative at €293m, against a positive €596m a year earlier. A MarketScreener analysis put the weak cash flow down mainly to payments linked to the group's legal cases.

The New Targets

2026 outlookNewPrevious
EBITDA before special items (currency-adjusted)€9.8bn to €10.3bn€9.6bn to €10.1bn
Pharmaceuticals EBITDA margin25% to 27%23% to 25%
Free cash flow-€1.5bn to -€0.5bn-€2.5bn to -€1.5bn
Net financial debt at year end€28bn to €29bn€29bn to €30bn

Bayer confirmed its other group guidance and now expects pharmaceutical sales toward the top of its range. Net financial debt fell to €31.08bn at the end of September, helped by a €3bn payment from Apollo Global Management for a minority stake in a new entity holding its long-acting contraceptive business.

What Investors Watch Now

Points to watch

  • The court decision on the $7.25bn Roundup settlement, which Bayer expects before Christmas.
  • Whether the Aretino verdict sets the pattern for later Roundup trials after the Durnell ruling.
  • Pharma momentum from Nubeqa and Kerendia, which reduce reliance on older drugs such as Xarelto and Eylea.
  • Crop Science, where profit fell sharply, and Consumer Health, where profit slipped.

Union Investment portfolio manager Markus Manns told Reuters that court approval of the settlement would sharply reduce Bayer's litigation risk and let management focus on running the business. After last week's verdict and today's upgrade, that ruling is now the main event for the shares.

Sources

Related stories

Markets

Stellantis Leaps 15% and the DAX Gains 2.5% as Results Split Europe's Winners and Losers

The DAX rose 2.53% this week and the STOXX 600 1.73% as earnings split Europe. Stellantis jumped 15.38% in a day on a revenue beat; Adyen sank 13.35% after cutting its margin…

Business

Bayer Wins FDA Approval for Sunharbo, the First Factor XIa Blood Thinner in the US

Bayer shares rose about 1.5% to their highest since May 2023 after the FDA approved Sunharbo, the first Factor XIa blood thinner in the US, which cut repeat strokes by 26% in its…

Markets

Bond Rout Drags Europe's Banks Lower as Infineon Surges 14% on the AI Chip Trade

The US 10-year yield hit 5.34%, its highest since 2002, and BNP Paribas fell 7.29% on the week as banks led Europe lower. Infineon rose 13.98%, with 8.78% on Friday alone, as money…

Investing

Rheinmetall Shares Slump as Delayed Army Contracts Force a Guidance Cut

Rheinmetall shares fell as much as 16 percent after the defence group cut its 2026 sales forecast to about €13.2 billion, blaming delays to German army contracts and ammunition…

Markets

Bitcoin Falls to $62,000 as $2bn of Leveraged Bets Are Wiped Out in Sixth Weekly Loss

Bitcoin fell to about $62,000 at the weekend as $2bn of leveraged bets were liquidated, its sixth straight weekly loss. It was back near $65,000 on Monday, with $60,000 the next…

Markets

Copper Hits a Four-Month Low at $13,210 as AI Doubts Drag European Miners Down 2.3%

Copper fell to $13,210 a tonne on Monday, a four-month low about 10% below September's record, as AI doubts and weak Chinese data hit metals and Europe's basic resources shares…

Markets

Bessent Urges an Outside CEO for Nvidia as Shares Fall 4.1% Before Results

Treasury Secretary Scott Bessent wants Nvidia to hire an outside chief executive, the board is not discussing Jensen Huang's return, and the shares fell 4.1% on Monday, a day…

Markets

Chip Index Sinks 5.28% With All 30 Stocks Down, Dragging the Nasdaq 2.49% Before Nvidia

The Philadelphia Semiconductor Index fell 5.28% on Monday 16 November with all 30 members down, pulling the Nasdaq 2.49% lower and the Dow down 739 points before Nvidia reports.